DDInter1666 DDInter1802
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Sildenafil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Sildenafil {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Sildenafil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Sildenafil {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Sildenafil {u} (Compound) causes {v} (Side Effect) Rectal haemorrhage
Rectal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Sildenafil {u} (Compound) causes {v} (Side Effect) Cerebral haemorrhage
Cerebral haemorrhage {u} (Side Effect) is caused by {v} (Compound) Fingolimod
Fingolimod {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Sildenafil {u} (Compound) binds {v} (Gene) PDE6C
PDE6C {u} (Gene) is bound by {v} (Compound) Dipyridamole
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Sildenafil {u} (Compound) causes {v} (Side Effect) Cerebral haemorrhage
Cerebral haemorrhage {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Sildenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Sildenafil (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Sildenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Sildenafil (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Sildenafil (Compound) causes Rectal haemorrhage (Side Effect) and Rectal haemorrhage (Side Effect) is caused by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Sildenafil (Compound) causes Cerebral haemorrhage (Side Effect) and Cerebral haemorrhage (Side Effect) is caused by Fingolimod (Compound) and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Sildenafil (Compound) binds PDE6C (Gene) and PDE6C (Gene) is bound by Dipyridamole (Compound) and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Sildenafil (Compound) causes Cerebral haemorrhage (Side Effect) and Cerebral haemorrhage (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor